| Item Type | Name |
|
Concept
|
Angiotensin Receptor Antagonists
|
|
Academic Article
|
Angiotensin II receptor blockers in hypertension and renal disease.
|
|
Academic Article
|
Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease.
|
|
Academic Article
|
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
|
|
Academic Article
|
The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.
|
|
Academic Article
|
Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial.
|
|
Academic Article
|
Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring.
|
|
Academic Article
|
Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker.
|
|
Academic Article
|
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
|
|
Academic Article
|
How to adjust ACE inhibitors and ARBs in diabetes?
|
|
Academic Article
|
Clinical implications of blockade of the renin-angiotensin system in management of hypertension.
|
|
Academic Article
|
The role of calcium antagonists in chronic kidney disease.
|
|
Academic Article
|
Blood pressure control and nephroprotection in diabetes.
|
|
Academic Article
|
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
|
|
Academic Article
|
Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
|
|
Academic Article
|
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
|
|
Academic Article
|
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
|
|
Academic Article
|
Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial.
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
|
|
Academic Article
|
Antihypertensive therapy in the presence of proteinuria.
|
|
Academic Article
|
Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient?
|
|
Academic Article
|
Slowing nephropathy progression: focus on proteinuria reduction.
|
|
Academic Article
|
Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
|
|
Academic Article
|
ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?
|
|
Academic Article
|
Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.
|
|
Academic Article
|
Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade.
|
|
Academic Article
|
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.
|
|
Academic Article
|
Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons?
|
|
Academic Article
|
Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?
|
|
Academic Article
|
Resistant hypertension: an overview of evaluation and treatment.
|
|
Academic Article
|
The current state of RAAS blockade in the treatment of hypertension and proteinuria.
|
|
Academic Article
|
Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians.
|
|
Academic Article
|
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
|
|
Academic Article
|
Are there effects of renin-angiotensin system antagonists beyond blood pressure control?
|
|
Academic Article
|
More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors.
|
|
Academic Article
|
Influence of microalbuminuria in achieving blood pressure goals.
|
|
Academic Article
|
Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
|
|
Academic Article
|
Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers.
|
|
Academic Article
|
Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells.
|
|
Academic Article
|
Effects of angiotensin II receptor blockers on diabetic nephropathy.
|
|
Academic Article
|
Combination therapy in hypertension.
|
|
Academic Article
|
Intensive blood-pressure control in hypertensive chronic kidney disease.
|
|
Academic Article
|
Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.
|
|
Academic Article
|
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.
|
|
Academic Article
|
Dual RAAS blockade is desirable in kidney disease: con.
|
|
Academic Article
|
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.
|
|
Academic Article
|
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.
|
|
Academic Article
|
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.
|
|
Academic Article
|
The author replies.
|
|
Academic Article
|
The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control.
|
|
Academic Article
|
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.
|
|
Academic Article
|
Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.
|
|
Academic Article
|
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy.
|
|
Academic Article
|
Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
|
|
Academic Article
|
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|
|
Academic Article
|
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
|
|
Academic Article
|
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
|
|
Academic Article
|
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
|
|
Academic Article
|
Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.
|
|
Academic Article
|
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
|
|
Academic Article
|
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
|
|
Academic Article
|
Mineralocorticoid antagonists in chronic kidney disease.
|
|
Academic Article
|
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension.
|
|
Academic Article
|
Baseline characteristics and enrichment results from the SONAR trial.
|
|
Academic Article
|
Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment.
|
|
Academic Article
|
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
|
|
Academic Article
|
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
|
|
Academic Article
|
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
|
|
Academic Article
|
Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.
|
|
Academic Article
|
Optimizing Blood Pressure Control Without Adding Anti-Hypertensive Medications.
|
|
Academic Article
|
Novel antihypertensive agents for resistant hypertension: what does the future hold?
|
|
Academic Article
|
Slowing the Progression of Diabetic Kidney Disease.
|